IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF- I and IGF-II. IGF-BP5 is a 28.6 kDa cysteine-rich secreted protein produced by vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts or osteoblasts. Data shows that IGFBP-5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGFBP-5 overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole-body growth inhibition and retarded muscle development. Recombinant human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues.
Human IGFBP5 expressed in E.coli
CAT# CSC-CTK0205-25 (25 μg); CAT# CSC-CTK0205-125 (125 μg)
Greater than 98% as determined by SDS-PAGE and RP-HPLC analysis.
The ED50 was determined by its ability to inhibit IGF-II induced proliferation of MCF-7 is < 0.3 μg/ml in the presence of 15 ng/ml of human IGF-II.
Less than 1 EU/μg.
Lyophilized (freeze-dried) powder.
Please centrifuge product briefly before opening vial. The lyophilized protein should be reconstituted in sterile, ultra-pure water to a concentration of 0.1-1.0 mg/ml. This solution can then be diluted into other aqueous buffers and stored at -20°C for future use.
Storage & Stability
The lyophilized protein, though stable at room temperature for up to 3 weeks, is best stored desiccated at -20°C. Reconstituted rHu IGFBP-5 should be used immediately or stored long-term in undiluted working aliquots at -20°C. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid repeated freeze-thaw cycles.
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon.